Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.61 |
| ▸ | FAAH | O00519 | 5/20 | 0.61 |
| ▸ | NAAA | Q02083 | 1/20 | 0.58 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.54 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | SELP | P16109 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258718 | 1.00 | CASP2 (0.61) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL258406 | 1.00 | CASP2 (0.61) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL11051906 | 1.00 | CASP2 (0.61) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL11228741 | 1.00 | CASP2 (0.61) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL258662 | 1.00 | CASP2 (0.61) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL6856630 | 1.00 | CASP2 (0.61) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL10882190 | 1.00 | CASP2 (0.61) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL233312 | 1.00 | CASP2 (0.61) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL21274180 | 1.00 | CASP2 (0.61) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL31510848 | 1.00 | CASP2 (0.61) | CASP2FAAHNAAADNM1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3551162-B1 | COMPOSITION SUITABLE FOR CLEANSING | OREAL (FR) | 2024-06-26 | — | — | EP | claimed |
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | UNIV CALIFORNIA (US) | 2026-03-19 | — | — | US | disclosed |
| US-12559611-B2 | Hydrophobic alginic acid particle group and method for producing same | NISSHINBO HOLDINGS INC. (JP) | 2026-02-24 | — | — | US | disclosed |
| US-20260043065-A1 | Methods of Administering 3,4-Diaminopyridine | SERB SA (BE) | 2026-02-12 | — | — | US | disclosed |
| EP-4640751-A1 | MARINE BIODEGRADABLE POLYMER PARTICLE GROUPS AND PRODUCTION METHOD FOR SAME | Nisshinbo Holdings Inc. (JP) | 2025-10-29 | — | — | EP | disclosed |
| US-12441850-B2 | Amphiphilic alginic acid particle group and method for producing same | NISSHINBO HOLDINGS INC. (JP) | 2025-10-14 | — | — | US | disclosed |
| US-12359146-B2 | Personal cleansing composition comprising a mixture of two polyglycerol fatty acid esters and a sugar fatty acid ester | MERRY PLUS CORPORATION (JP) | 2025-07-15 | — | — | US | disclosed |
| US-20250213451-A1 | AN ORAL CARE COMPOSITION COMPRISING A GLYCOLIPID AND A MILD SURFACTANT | BASF SE (DE) | 2025-07-03 | — | — | US | disclosed |
| WO-2025092982-A1 | A STABLE MULTIPLE EMULSION COMPOSITION | BASF SE (DE) | 2025-05-08 | — | — | WO | disclosed |
| US-20250143993-A1 | COSMETIC | SHISEIDO COMPANY, LTD. (JP) | 2025-05-08 | — | — | US | disclosed |
| EP-1372611-A2 | PHARMACEUTICAL COMPOSITION COMPRISING A POORLY WATER-SOLUBLE ACTIVE INGREDIENT, A SURFACTANT AND A WATER-SOLUBLE POLYMER | Novartis AG (CH) | 2004-01-02 | — | — | EP | disclosed |
| US-20030091732-A1 | Aqueous surfactant solution for developing coating film layer | AZ ELECTRONIC MATERIALS USA CORP. | 2003-05-15 | — | — | US | disclosed |
| EP-1308787-A1 | AQUEOUS SURFACTANT SOLUTION FOR DEVELOPING COATING FILM LAYER | Clariant International Ltd. (CH) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002076432-A2 | PHARMACEUTICAL COMPOSITION COMPRISING A POORLY WATER-SOLUBLE ACTIVE INGREDIENT, A SURFACTANT AND A WATER-SOLUBLE POLYMER | NOVARTIS AG (CH) | 2002-10-03 | — | — | WO | disclosed |
| EP-0083084-B1 | POLYMER MOULDING COMPOSITION CONTAINING A FILLER, PROCESS FOR ITS PREPARATION AND ITS USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-04-16 | — | — | EP | disclosed |
| US-4456710-A | ALKALI OR ALKALINE EARTH METAL ORGANIC SULFONATES AS ADHESION PROMOTERS; DISCOLORATION INHIBITION; ACETAL RESINS | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-06-26 | — | — | US | disclosed |
| EP-0083084-A2 | Polymer moulding composition containing a filler, process for its preparation and its use | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-07-06 | — | — | EP | disclosed |
| US-4307009-A | POLYOLEFIN, ALKALINE EARTH CARBONATE, ALKYL OR ALKENYL SULFONIC ACID OR ETHER SULFATE | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-12-22 | — | — | US | disclosed |
| EP-0017038-A1 | Polymeric moulding compounds containing fillers and process for their manufacture | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-10-15 | — | — | EP | disclosed |
| US-4212966-A | AGITATING MELT WITH SURFACTANT TO FORM DISPERSION | NATIONAL DISTILLERS & CHEMICAL CORPORATION (US) | 1980-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260043065-A1 | Methods of Administering 3,4-Diaminopyridine | NAT1, SAT1, NANS | CASP2 3117/4885FAAH 2280/4885NAAA 318/4885 |
| US-20250213451-A1 | AN ORAL CARE COMPOSITION COMPRISING A GLYCOLIPID AND A MILD SURFACTANT | SMURF1, PHOSPHO1, SGMS1 | CASP2 3368/4885FAAH 1197/4885NAAA 587/4885 |
| US-20250143993-A1 | COSMETIC | SLC7A1, SLC14A1, H1-0 | CASP2 3630/4885FAAH 2182/4885NAAA 2995/4885 |
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | IDO1, INMT, IDO2 | CASP2 3492/4885FAAH 384/4885NAAA 584/4885 |
| US-12559611-B2 | Hydrophobic alginic acid particle group and method for producing same | ALG3, ALG1, HACD3 | CASP2 3030/4885FAAH 2324/4885NAAA 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.